Several candidates relegated to the R&D graveyard re-emerged from their tombs this year and now headline the pharma developmental slate for 2020.
MM&M estimates that revenue for the growing conglomerate increased 7.6% in 2018, to an estimated $245 million from 2017’s sum of $227.8 million.
Triple Threat Communications founder and leader Tim Frank makes it a point to mind the culture — which, he says, is all about putting clients first.
Revenue jumped to $6.4 million in 2018 — a 156% increase.
Revenue grew from $4.7 million in 2017 to $9.8 million in 2018.
Relevate Health Group saw a 4.9% bump in revenue, from $14.2 million to $14.9 million.
Within its healthcare vertical, P+N’s revenue jumped 23.7%, from $5.9 million at the end of 2017 to $7.3 million by the close of 2018.
For Pacific Communications president Craig Sullivan, 2018 provided ample cause for celebration.
MEI increased revenue to $29 million from $26 million in 2017, an 11.5% surge.
MedThink’s revenue climbed 22.4% to $15.3 million.
Get the most out of
Register for free and enjoy unlimited access to: